U.S. markets closed

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.9006+0.0106 (+1.19%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.8900
Open0.8800
Bid0.8932 x 800
Ask0.9000 x 900
Day's Range0.8500 - 0.9287
52 Week Range0.6400 - 2.2200
Volume2,172,258
Avg. Volume3,870,025
Market Cap183.971M
Beta (5Y Monthly)2.64
PE Ratio (TTM)N/A
EPS (TTM)-0.1180
Earnings DateMay 10, 2021 - May 14, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Matinas BioPharma to Present at the Needham Healthcare Conference
    GlobeNewswire

    Matinas BioPharma to Present at the Needham Healthcare Conference

    BEDMINSTER, N.J., April 08, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a Company overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 4:30 p.m. ET. The Company will also host investor meetings during the conference. A live webcast of the Company’s presentation will be available on the IR Calendar page of the Investors section of the Company’s website (www.matinasbiopharma.com). A webcast replay will be accessible for 90 days following the live presentation. About Matinas BioPharma Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors. Matinas is developing a portfolio of products based upon its proprietary LNC drug delivery platform, which can solve complex challenges relating to the safe and effective intracellular delivery of both small and larger, more complex molecules. MAT2203 is an oral, LNC formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is currently enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the third quarter of 2021. MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF). LYPDISO™, the Company’s product candidate intended for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, recently announced data from the ENHANCE-IT study, a head-to-head crossover study evaluating LYPDISO vs. Vascepa in patients with elevated triglycerides. Data demonstrating superior levels of eicosapentaenoic acid (EPA) in the blood with LYPDISO support the potential superior cardioprotective effect of LYPDISO vs. Vascepa. The Company has initiated a process to identity and secure a potential partner to continue development of LYPDISO toward a cardiovascular outcomes indication. Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the LNC platform delivery technology, the Company’s strategic focus and the future development of its product candidates, including MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use. Investor and Media Contacts Peter VozzoWestwicke/ICR443-213-0505peter.vozzo@westwicke.com

  • We're Not Very Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Rate
    Simply Wall St.

    We're Not Very Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Rate

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • Matinas Posts Quarterly Loss In-Line With Expectations
    SmarterAnalyst

    Matinas Posts Quarterly Loss In-Line With Expectations

    Matinas BioPharma incurred a loss of $0.03 per share in 4Q, which met analysts’ expectations. The reported loss by the biopharmaceutical company was smaller than the prior-year quarter’s loss of $0.04 per share. Matinas’ (MTNB) research and development expenses increased 2.9% on a year-over-year basis to $3.5 million in the quarter, while total general and administrative expenses surged 30.4% to $3 million. Matinas CEO Jerome D. Jabbour said, “The completion of the head-to-head ENHANCE-IT trial of LYPDISO vs. Vascepa and the results which support the potential for LYPDISO to demonstrate a superior cardioprotective effect to Vascepa, have positioned us to identify and potentially secure a global partner for the continued development of this promising, next-generation drug.” (See Matinas stock analysis on TipRanks) On Feb. 1, Maxim Group analyst Jason McCarthy maintained a Buy rating and a price target of $3 (168% upside potential). According to McCarthy, “the overall data set for ENHANCE is actually quite good and the next step is likely an outcomes trial, potentially with a partner.” Furthermore, the analyst said, “In addition, while we await next steps for Lypdiso, don’t forget Matinas has a pipeline with updates expected in 2021 (MAT2203, MAT2501, LNC-based collaborations) and the company has cash runway likely through 2022, ~$60M. Combined, we view MTNB shares as oversold and would Buy on the weakness.” Shares have rallied 60% over the past year, while Wall Street analysts are still bullish about the stock. The Strong Buy consensus rating boasts 4 unanimous Buy ratings. Looking ahead, the average analyst price target stands at $3.67, putting the upside potential at about 227.7% over the next 12 months. Related News: KBR Provides Long-Term Financial Targets; Shares Pop 13% Bioventus’ 4Q Results Outperform Analysts’ Expectations Satsuma Posts Wider-Than-Feared Quarterly Loss More recent articles from Smarter Analyst: Tencent To Buy Back $1B In Stock; Shares Gain Pre-Market Johnson & Johnson Signs Single-Shot COVID-19 Vaccine Deal With AVAT Accenture To Snap Up Cygni In Cloud Push Chipotle Invests In Nuro In Autonomous Delivery Push